SPDR S&P Pharmaceuticals ETF
Price through Oct 1 · Flows through Sep 30. Figures use the latest available records, not a live quote. Fund details retrieved Oct 1. Holdings snapshot retrieved Oct 1.
In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 3Y SHOWN · NET +$218M OVER THIS RANGE
Money is leaving — −$15M in net outflows over the past month, about 2.9% of the fund's asset base, while the price has returned +13.9% so far this year. At 0.35% a year it is not the cheapest way in — AVIE has a reported fee of 0.25%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | AMLXAMYLYX PHARMACEUTICALS | 2.04% | $28.08 | -3.5% | ||
| 2 | MBXMBX Biosciences | 2.72% | $56.55 | -3.5% | ||
| 3 | OMEROMEROS | 1.42% | $18.47 | -3.0% | ||
| 4 | DFTXDefinium Therapeutics | 3.09% | $37.60 | -1.2% | ||
| 5 | CORTCORCEPT THERAPEUTICS | 1.70% | $114.03 | -1.0% | ||
| 6 | AMRXAMNEAL PHARMACEUTICALS | 1.72% | $20.07 | -0.3% | ||
| 7 | MANEVERADERMICS INC | 2.02% | $117.22 | -3.3% | ||
| 8 | PRGOPERRIGO CO | 1.42% | $14.02 | -5.0% | ||
| 9 | ELVNENLIVEN THERAPEUTICS | 2.09% | $46.21 | +0.8% | ||
| 10 | TARSTARSUS PHARMACEUTICALS | 1.57% | $75.46 | -4.0% | ||
| 11 | EWTXEDGEWISE THERAPEUTICS | 1.88% | $40.48 | -0.3% | ||
| 12 | ETONETON PHARMACEUTICALS | 1.30% | $51.98 | +1.0% | ||
| 13 | LGNDLIGAND PHARMACEUTICALS | 1.94% | $302.74 | -3.1% | ||
| 14 | NUVBNUVATION BIO | 1.89% | $5.56 | -0.7% | ||
| 15 | MRKMERCK & CO | 1.65% | $143.81 | -1.0% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 41| 1 week | -3.5% |
| 1 month | -9.0% |
| 3 months | -2.4% |
| 6 months | +24.2% |
| YTD | +13.9% |
| 1 year | +31.4% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | −$13M |
| 1 month | −$15M |
| 3 months | +$115M |
| YTD | +$252M |
| 1 year | +$274M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 3.1% of the book; the top ten carry 22%. Spread across 66+ names, it behaves like roughly 60 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| LLY ELI LILLY | $30M | $32M |
| LQDA LIQUIDIA | $13M | $17M |
| JNJ JOHNSON & JOHNSON | $3M | $3M |
| MRK MERCK & CO | $3M | $2M |
| NKTR NEKTAR THERAPEUTICS | $2M | $2M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat XPH on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.5B | +$286M | -32bp on fee · 79× the assets · +$286M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.2B | +$199M | -32bp on fee · 35× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.9B | +$497M | -31bp on fee · 63× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$575M | -31bp on fee · 45× the assets · +$575M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -31bp on fee · 35× the assets · +$412M in over the month | Head-to-head |